US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Serina Therapeutics, Inc.

3.54

+0.820030.15%

Post-market: 3.32-0.2200-6.21%19:59 EST

Volume:66.37M

Turnover:274.22M

Market Cap:37.75M

PE:-1.99

High:4.08

Open:3.84

Low:3.41

Close:2.72

52wk High:7.92

52wk Low:1.71

Shares:10.66M

Float Shares:5.19M

Volume Ratio:43.64

T/O Rate:1277.92%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.7830

EPS(LYR):-1.5139

ROE:-485.36%

ROA:-137.85%

PB:-11.87

PE(LYR):-2.34

Loading ...

Overview Company News Filings

Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Sale of Common Shares

This Is Why Serina Therapeutics Stock (SER) Rocketed Today

What Sparked Serina Therapeutics (SER) 35% After-Hours Surge?

Benzinga_recent_news

Serina Therapeutics announces FDA clearance of SER-252 new drug application

FDA Clears IND Application for Serina Therapeutics' SER-252 in Advanced Parkinson's Disease

Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares

Serina Therapeutics Faces NYSE Delisting Risk Over Shareholders' Equity Deficiency

Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares

Chief Scientific Officer Randall Moreadith Reports Sale of Serina Therapeutics Inc. Common Shares

Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares

Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares

Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Sale of Common Shares

Serina Therapeutics Appoints Dr. Joshua Thomas as Vice President and Head of Chemistry

Serina Therapeutics Strengthens Leadership Team With Appointment of DR. Joshua Thomas as Vp, Head of Chemistry

THOMSON REUTERS

Chief Scientific Officer Randall Moreadith Reports Disposal of Serina Therapeutics Inc. Common Shares

Serina Therapeutics Inc - Submits Complete Response to FDA Clinical Hold Letter for Ser-252 Program- SEC Filing

THOMSON REUTERS

Serina Therapeutics Inc - Continues Site Start-up and Regulatory Activities in Australia - SEC Filing

THOMSON REUTERS

Serina Therapeutics Submits Complete Response to FDA Clinical Hold for SER-252

Chief Scientific Officer Randall Moreadith Reports Disposal of Serina Therapeutics Inc. Common Shares

Chief Scientific Officer Randall Moreadith Disposes Common Shares of Serina Therapeutics Inc

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SER/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SER","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SER\",,,,,undefined,":{"symbol":"SER","market":"US","secType":"STK","nameCN":"Serina Therapeutics, Inc.","latestPrice":3.54,"timestamp":1769720400000,"preClose":2.72,"halted":0,"volume":66372909,"hourTrading":{"tag":"盘后","latestPrice":3.32,"preClose":3.54,"latestTime":"19:59 EST","volume":512974,"amount":1739808.666,"timestamp":1769734782615,"change":-0.22,"changeRate":-0.062147,"amplitude":0.110169},"delay":0,"changeRate":0.30147058823529405,"floatShares":5193821,"shares":10664064,"eps":-1.783,"marketStatus":"Not Yet Opened","change":0.82,"latestTime":"01-29 16:00:00 EST","open":3.84,"high":4.08,"low":3.41,"amount":274223675.81991273,"amplitude":0.246324,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.783,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769763600000},"marketStatusCode":0,"adr":0,"exchange":"AMEX","adjPreClose":2.72,"preHourTrading":{"tag":"盘前","latestPrice":3.81,"preClose":2.72,"latestTime":"09:29 EST","volume":12585515,"amount":54334625.851025,"timestamp":1769696999999,"change":1.09,"changeRate":0.400735,"amplitude":0.625},"postHourTrading":{"tag":"盘后","latestPrice":3.32,"preClose":3.54,"latestTime":"19:59 EST","volume":512974,"amount":1739808.666,"timestamp":1769734782615,"change":-0.22,"changeRate":-0.062147,"amplitude":0.110169},"volumeRatio":43.640083},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SER\",,,,,undefined,":{"symbol":"SER","floatShares":5193821,"roa":"-137.85%","roe":"-485.36%","lyrEps":-1.513928,"volumeRatio":43.640083,"shares":10664064,"dividePrice":0,"high":4.08,"amplitude":0.246324,"preClose":2.72,"low":3.41,"week52Low":1.7101,"pbRate":"-11.87","psRate":"325.44","week52High":7.92,"institutionHeld":0,"latestPrice":3.54,"eps":-1.783,"divideRate":0,"volume":66372909,"delay":0,"ttmEps":-1.783,"open":3.84,"prevYearClose":1.913,"prevWeekClose":2.87,"prevMonthClose":1.913,"prevQuarterClose":1.913,"fiveDayClose":2.96,"twentyDayClose":2.011,"sixtyDayClose":5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SER\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"SER","fiscalQuarterEnding":"2025/09","expectedEps":-0.47,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2025-08-11","symbol":"SER","fiscalQuarterEnding":"2025/06","expectedEps":-0.36,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-03-24","symbol":"SER","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2024-11-12","symbol":"SER","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":0.13},{"market":"US","date":"2024-08-09","symbol":"SER","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"post","actualEps":0.51}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SER\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SER\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1752469200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SER\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SER","date":"2026-01-28","current":-1.985418,"percent":0.865909,"low":-65.600015,"twenty":-12.310713,"median":-6.032011,"eighty":-3.272364,"high":37.356482,"avg":-11.959424,"sd":21.341143,"marketCap":29219535},"quantilePoints":[{"date":"2024-04-05","current":29.141387,"twenty":30.584579,"median":32.083279,"eighty":33.732959,"marketCap":105541506},{"date":"2024-04-12","current":17.770243,"twenty":17.783016,"median":23.543628,"eighty":32.232039,"marketCap":93646584},{"date":"2024-04-19","current":17.456349,"twenty":17.731924,"median":17.945869,"eighty":31.172957,"marketCap":91992413},{"date":"2024-04-26","current":14.673941,"twenty":16.787882,"median":17.778226,"eighty":29.502185,"marketCap":77329529},{"date":"2024-05-03","current":14.209648,"twenty":14.673941,"median":17.57865,"eighty":21.283439,"marketCap":74882770},{"date":"2024-05-10","current":14.050147,"twenty":14.209648,"median":17.078432,"eighty":18.800885,"marketCap":74042223},{"date":"2024-05-17","current":12.820759,"twenty":14.187327,"median":15.966076,"eighty":18.090969,"marketCap":67563528},{"date":"2024-05-24","current":15.167772,"twenty":14.187327,"median":15.718602,"eighty":17.818141,"marketCap":79931945},{"date":"2024-05-31","current":-13.721878,"twenty":13.545619,"median":15.079879,"eighty":17.786209,"marketCap":79931945},{"date":"2024-06-07","current":-14.08298,"twenty":12.926135,"median":14.744671,"eighty":17.776629,"marketCap":82035417},{"date":"2024-06-14","current":-14.564515,"twenty":-13.557216,"median":14.673941,"eighty":17.770243,"marketCap":84840426},{"date":"2024-06-21","current":-15.922863,"twenty":-13.825876,"median":14.209648,"eighty":17.731924,"marketCap":92753004},{"date":"2024-06-28","current":-12.919404,"twenty":-13.944317,"median":14.209648,"eighty":17.655287,"marketCap":75257414},{"date":"2024-07-05","current":-11.364849,"twenty":-13.990538,"median":14.209648,"eighty":17.52973,"marketCap":66201907},{"date":"2024-07-12","current":-11.153551,"twenty":-13.799876,"median":13.810656,"eighty":17.339222,"marketCap":64971062},{"date":"2024-07-15","current":-13.477836,"twenty":-13.773877,"median":13.571165,"eighty":17.280659,"marketCap":78510363},{"date":"2024-08-02","current":-12.964682,"twenty":-13.747877,"median":13.539233,"eighty":17.222095,"marketCap":75521166},{"date":"2024-08-09","current":-11.364095,"twenty":-13.723872,"median":13.251843,"eighty":17.027373,"marketCap":66197511},{"date":"2024-08-16","current":-8.441425,"twenty":-13.721878,"median":2.384851,"eighty":16.171527,"marketCap":59150297},{"date":"2024-08-23","current":-10.330099,"twenty":-13.617881,"median":-8.582039,"eighty":15.966076,"marketCap":72384510},{"date":"2024-08-30","current":-10.13985,"twenty":-13.52255,"median":-9.00413,"eighty":15.966076,"marketCap":71051408},{"date":"2024-09-06","current":-10.104487,"twenty":-13.488788,"median":-9.975078,"eighty":15.85112,"marketCap":70803616},{"date":"2024-09-13","current":-7.831133,"twenty":-13.268937,"median":-9.379361,"eighty":15.707426,"marketCap":54873890},{"date":"2024-09-20","current":-7.554188,"twenty":-13.112179,"median":-8.839249,"eighty":15.365752,"marketCap":52933298},{"date":"2024-09-27","current":-9.43006,"twenty":-13.019016,"median":-9.049816,"eighty":15.0623,"marketCap":66077809},{"date":"2024-10-04","current":-8.251303,"twenty":-12.937515,"median":-8.845695,"eighty":14.905865,"marketCap":57818083},{"date":"2024-10-11","current":-8.580848,"twenty":-12.554189,"median":-8.732946,"eighty":14.786183,"marketCap":60127254},{"date":"2024-10-18","current":-9.769745,"twenty":-12.214089,"median":-8.764633,"eighty":14.702233,"marketCap":68458031},{"date":"2024-10-25","current":-8.872369,"twenty":-11.941393,"median":-8.872369,"eighty":14.673941,"marketCap":62169982},{"date":"2024-10-31","current":-8.568173,"twenty":-11.747964,"median":-8.847019,"eighty":14.628789,"marketCap":60038439},{"date":"2024-11-08","current":-5.742165,"twenty":-11.5456,"median":-8.764633,"eighty":14.420496,"marketCap":40236191},{"date":"2024-11-15","current":-6.048407,"twenty":-11.364849,"median":-8.720054,"eighty":14.209648,"marketCap":44459880},{"date":"2024-11-22","current":-5.928673,"twenty":-11.364547,"median":-8.695365,"eighty":14.209648,"marketCap":43570682},{"date":"2024-11-29","current":-6.352149,"twenty":-11.321986,"median":-8.600455,"eighty":14.209648,"marketCap":46682874},{"date":"2024-12-06","current":-7.456945,"twenty":-11.110513,"median":-8.568173,"eighty":14.187327,"marketCap":54802179},{"date":"2024-12-13","current":-6.006451,"twenty":-10.914992,"median":-8.561836,"eighty":14.088465,"marketCap":44142287},{"date":"2024-12-20","current":-7.07266,"twenty":-10.789111,"median":-8.479449,"eighty":13.954351,"marketCap":51978012},{"date":"2024-12-27","current":-6.747673,"twenty":-10.659517,"median":-8.390726,"eighty":13.571165,"marketCap":49589633},{"date":"2025-01-03","current":-6.517639,"twenty":-10.562175,"median":-8.162579,"eighty":13.520073,"marketCap":47899077},{"date":"2025-01-10","current":-5.904214,"twenty":-10.499761,"median":-8.051056,"eighty":13.363605,"marketCap":43390929},{"date":"2025-01-17","current":-6.07035,"twenty":-10.463782,"median":-7.83254,"eighty":13.258229,"marketCap":44611886},{"date":"2025-01-24","current":-6.006451,"twenty":-10.451708,"median":-7.712623,"eighty":13.14966,"marketCap":44142287},{"date":"2025-01-31","current":-5.878654,"twenty":-10.421318,"median":-7.617562,"eighty":12.926135,"marketCap":43203089},{"date":"2025-02-07","current":-5.878654,"twenty":-10.364245,"median":-7.402632,"eighty":5.571028,"marketCap":43203089},{"date":"2025-02-14","current":-5.955332,"twenty":-10.299629,"median":-7.207741,"eighty":-5.38422,"marketCap":43766608},{"date":"2025-02-21","current":-6.249265,"twenty":-10.231108,"median":-7.041606,"eighty":-5.510713,"marketCap":45926762},{"date":"2025-02-28","current":-6.380056,"twenty":-10.13985,"median":-6.713492,"eighty":-5.574659,"marketCap":46887966},{"date":"2025-03-07","current":-6.326216,"twenty":-10.13478,"median":-6.696682,"eighty":-5.743169,"marketCap":46492287},{"date":"2025-03-14","current":-5.532074,"twenty":-10.112497,"median":-6.684888,"eighty":-5.743169,"marketCap":40656021},{"date":"2025-03-21","current":-6.110856,"twenty":-10.104487,"median":-6.616553,"eighty":-5.743169,"marketCap":44909571},{"date":"2025-03-28","current":-4.234631,"twenty":-10.098885,"median":-6.511249,"eighty":-5.532216,"marketCap":47178021},{"date":"2025-04-04","current":-4.894342,"twenty":-10.073941,"median":-6.460817,"eighty":-4.926436,"marketCap":54527860},{"date":"2025-04-11","current":-4.279206,"twenty":-10.051126,"median":-6.404799,"eighty":-4.716041,"marketCap":47674632},{"date":"2025-04-17","current":-4.680381,"twenty":-10.000427,"median":-6.391338,"eighty":-4.680381,"marketCap":52144128},{"date":"2025-04-25","current":-5.429242,"twenty":-9.949728,"median":-6.352149,"eighty":-4.680381,"marketCap":60487189},{"date":"2025-05-02","current":-4.733871,"twenty":-9.769745,"median":-6.319486,"eighty":-4.680381,"marketCap":52740061},{"date":"2025-05-09","current":-5.121942,"twenty":-9.696231,"median":-6.287604,"eighty":-4.698211,"marketCap":57063554},{"date":"2025-05-16","current":-59.867974,"twenty":-10.063801,"median":-6.319486,"eighty":-4.716041,"marketCap":56216028},{"date":"2025-05-23","current":-62.521698,"twenty":-10.1145,"median":-6.352149,"eighty":-4.716041,"marketCap":58707874},{"date":"2025-05-30","current":-61.035612,"twenty":-10.269158,"median":-6.380056,"eighty":-4.730305,"marketCap":57312440},{"date":"2025-06-06","current":-63.15859,"twenty":-10.460251,"median":-6.404799,"eighty":-4.739577,"marketCap":59305916},{"date":"2025-06-13","current":-62.893218,"twenty":-10.844881,"median":-6.460817,"eighty":-4.756693,"marketCap":59056732},{"date":"2025-06-20","current":-61.035612,"twenty":-11.364397,"median":-6.504859,"eighty":-4.787361,"marketCap":57312440},{"date":"2025-06-27","current":-65.069271,"twenty":-11.941393,"median":-6.601297,"eighty":-4.858682,"marketCap":61100045},{"date":"2025-07-03","current":-63.052442,"twenty":-12.946571,"median":-6.683774,"eighty":-4.897908,"marketCap":59206243},{"date":"2025-07-11","current":-62.585387,"twenty":-13.494265,"median":-6.687561,"eighty":-4.963879,"marketCap":58767678},{"date":"2025-07-18","current":-56.365062,"twenty":-13.727859,"median":-6.706215,"eighty":-5.054812,"marketCap":52926793},{"date":"2025-07-25","current":-57.320401,"twenty":-14.163867,"median":-6.747673,"eighty":-5.06551,"marketCap":53823857},{"date":"2025-08-01","current":-58.806486,"twenty":-14.540367,"median":-7.140201,"eighty":-5.097711,"marketCap":55219290},{"date":"2025-08-08","current":-57.851146,"twenty":-16.339423,"median":-7.348318,"eighty":-5.123618,"marketCap":54322226},{"date":"2025-08-15","current":-4.477661,"twenty":-17.151414,"median":-7.290809,"eighty":-5.06551,"marketCap":56378234},{"date":"2025-08-22","current":-4.477661,"twenty":-16.339423,"median":-7.07266,"eighty":-4.840851,"marketCap":56378234},{"date":"2025-08-29","current":-4.176437,"twenty":-15.621008,"median":-6.732661,"eighty":-4.723173,"marketCap":52585516},{"date":"2025-09-05","current":-4.298555,"twenty":-15.168225,"median":-6.706215,"eighty":-4.683947,"marketCap":54123104},{"date":"2025-09-12","current":-4.152013,"twenty":-15.047483,"median":-6.687561,"eighty":-4.603418,"marketCap":52277998},{"date":"2025-09-19","current":-3.671682,"twenty":-14.552441,"median":-6.683774,"eighty":-4.480762,"marketCap":46230151},{"date":"2025-09-26","current":-4.054319,"twenty":-14.495088,"median":-6.586042,"eighty":-4.445795,"marketCap":51047928},{"date":"2025-10-03","current":-4.274131,"twenty":-14.455909,"median":-6.482838,"eighty":-4.363684,"marketCap":53815587},{"date":"2025-10-10","current":-4.670023,"twenty":-14.397862,"median":-6.433897,"eighty":-4.347636,"marketCap":58800259},{"date":"2025-10-17","current":-4.092547,"twenty":-14.188422,"median":-6.402621,"eighty":-4.323139,"marketCap":51529260},{"date":"2025-10-24","current":-4.322701,"twenty":-14.088758,"median":-6.364249,"eighty":-4.310147,"marketCap":54427122},{"date":"2025-10-31","current":-4.008855,"twenty":-14.036759,"median":-6.339182,"eighty":-4.297619,"marketCap":50475491},{"date":"2025-11-07","current":-3.448117,"twenty":-13.827869,"median":-6.299296,"eighty":-4.264361,"marketCap":43415245},{"date":"2025-11-14","current":-3.280733,"twenty":-13.729853,"median":-6.273601,"eighty":-4.236343,"marketCap":41307709},{"date":"2025-11-21","current":-2.15737,"twenty":-13.721878,"median":-6.249265,"eighty":-4.197811,"marketCap":40096880},{"date":"2025-11-28","current":-2.444254,"twenty":-13.721878,"median":-6.245456,"eighty":-4.152013,"marketCap":45428912},{"date":"2025-12-05","current":-1.990977,"twenty":-13.591882,"median":-6.147028,"eighty":-4.102049,"marketCap":37004302},{"date":"2025-12-12","current":-1.801633,"twenty":-13.505217,"median":-6.121468,"eighty":-4.090954,"marketCap":33485160},{"date":"2025-12-19","current":-1.524503,"twenty":-13.477836,"median":-6.11051,"eighty":-4.06246,"marketCap":28334418},{"date":"2025-12-26","current":-1.399995,"twenty":-13.199304,"median":-6.089519,"eighty":-4.041726,"marketCap":26020316},{"date":"2026-01-02","current":-1.097619,"twenty":-13.112179,"median":-6.083129,"eighty":-3.997732,"marketCap":20400354},{"date":"2026-01-09","current":-1.503274,"twenty":-13.019016,"median":-6.07035,"eighty":-3.774262,"marketCap":27939847},{"date":"2026-01-16","current":-1.543438,"twenty":-12.937515,"median":-6.048407,"eighty":-3.438074,"marketCap":28686332},{"date":"2026-01-23","current":-1.698355,"twenty":-12.675928,"median":-6.046598,"eighty":-3.349361,"marketCap":31565629},{"date":"2026-01-28","current":-1.572126,"twenty":-12.310713,"median":-6.032011,"eighty":-3.272364,"marketCap":29219535}],"updateTime":1769745017668},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SER\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607372770","title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2607372770","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2607372770?lang=en_us&edition=fundamental","pubTime":"2026-01-30 01:54","pubTimestamp":1769709272,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported a disposal of common shares of the company, according to a recent regulatory filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL4RRN7m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2607036423","title":"This Is Why Serina Therapeutics Stock (SER) Rocketed Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2607036423","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607036423?lang=en_us&edition=fundamental","pubTime":"2026-01-29 22:53","pubTimestamp":1769698383,"startTime":"0","endTime":"0","summary":"Serina Therapeutics stock was on the rise after the company received good news from the FDA.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/this-is-why-serina-therapeutics-stock-ser-rocketed-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/this-is-why-serina-therapeutics-stock-ser-rocketed-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2607000774","title":"What Sparked Serina Therapeutics (SER) 35% After-Hours Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2607000774","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607000774?lang=en_us&edition=fundamental","pubTime":"2026-01-29 13:09","pubTimestamp":1769663340,"startTime":"0","endTime":"0","summary":"Serina Therapeutics shares jumped nearly 35% after the FDA cleared its IND application for SER-252, advancing plans for a Phase 1b trial in advanced Parkinson's disease.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/29/Stock-Market-Trading-Graph.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/29/Stock-Market-Trading-Graph.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/01/50215493/what-sparked-serina-therapeutics-ser-35-after-hours-surge","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/01/50215493/what-sparked-serina-therapeutics-ser-35-after-hours-surge","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4150","SER","RSI","BK4139"],"gpt_icon":0},{"id":"2607723460","title":"Serina Therapeutics announces FDA clearance of SER-252 new drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2607723460","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607723460?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:31","pubTimestamp":1769635890,"startTime":"0","endTime":"0","summary":"Serina Therapeutics (SER) announced that the FDA has cleared its investigational new drug application for SER-252, an investigational therapy for a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/serina-therapeutics-announces-fda-clearance-of-ser-252-new-drug-application-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/serina-therapeutics-announces-fda-clearance-of-ser-252-new-drug-application-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2607740330","title":"FDA Clears IND Application for Serina Therapeutics' SER-252 in Advanced Parkinson's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2607740330","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607740330?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:03","pubTimestamp":1769634226,"startTime":"0","endTime":"0","summary":"Serina Therapeutics Inc. announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for SER-252, an investigational therapy for advanced Parkinson's disease. The clearance allows the company to proceed with regulatory and site-level activities to support the initiation of a planned Phase 1b registrational clinical study. The FDA has provided feedback supporting the proposed clinical trial design under a 505 New Drug Application  pathway. Phase 1b clinical site start-up and regulatory activities in Australia are also underway as part of the global registrational program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL3NvKVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2605443443","title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605443443","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605443443?lang=en_us&edition=fundamental","pubTime":"2026-01-22 08:17","pubTimestamp":1769041066,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL5MVZtn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2603935660","title":"Serina Therapeutics Faces NYSE Delisting Risk Over Shareholders' Equity Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2603935660","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603935660?lang=en_us&edition=fundamental","pubTime":"2026-01-16 05:03","pubTimestamp":1768511039,"startTime":"0","endTime":"0","summary":"Serina Therapeutics Inc. has received a deficiency notification from the New York Stock Exchange  regarding its stockholders' equity, which fell to $1.6 million as of September 30, 2025. The company has also reported losses in three of its four most recent fiscal years, putting it below the continued listing criteria under Sections 1003 and  of the NYSE American Company Guide. Serina must submit a compliance plan by February 8, 2026, outlining actions to regain compliance by July 9, 2027. Failure to submit an acceptable plan may result in delisting proceedings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL5wXrSD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2603838646","title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603838646","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603838646?lang=en_us&edition=fundamental","pubTime":"2026-01-15 01:57","pubTimestamp":1768413442,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 14, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL4Mzbr5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2602080033","title":"Chief Scientific Officer Randall Moreadith Reports Sale of Serina Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602080033","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602080033?lang=en_us&edition=fundamental","pubTime":"2026-01-10 01:28","pubTimestamp":1767979690,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported the disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDLt8GDq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Scientific Officer Randall Moreadith Reports Sale of Serina Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2595731785","title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595731785","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595731785?lang=en_us&edition=fundamental","pubTime":"2025-12-30 00:40","pubTimestamp":1767026447,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL49K6l3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2593172084","title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593172084","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593172084?lang=en_us&edition=fundamental","pubTime":"2025-12-24 03:05","pubTimestamp":1766516706,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL5tCL2Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2592955227","title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592955227","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592955227?lang=en_us&edition=fundamental","pubTime":"2025-12-17 07:59","pubTimestamp":1765929594,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported a disposal of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL977FGm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Serina Therapeutics Chief Scientific Officer Randall Moreadith Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2590549013","title":"Serina Therapeutics Appoints Dr. Joshua Thomas as Vice President and Head of Chemistry","url":"https://stock-news.laohu8.com/highlight/detail?id=2590549013","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590549013?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:15","pubTimestamp":1765487710,"startTime":"0","endTime":"0","summary":"Serina Therapeutics Inc. has appointed Dr. Joshua Thomas as Vice President and Head of Chemistry. Dr. Thomas will oversee internal and external chemistry efforts to optimize POZ-based drug candidates, supporting the company's development pipeline. He previously held scientific leadership roles at Mersana Therapeutics and has expertise in discovery chemistry and antibody drug conjugate technologies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLb7spWt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014013.SGD","BK4563","BK4112","SER","LU0314104364.USD","MRSN","SG9999014005.SGD","SG9999014039.USD","NDAQ","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","BK4588"],"gpt_icon":0},{"id":"2590036549","title":"Serina Therapeutics Strengthens Leadership Team With Appointment of DR. Joshua Thomas as Vp, Head of Chemistry","url":"https://stock-news.laohu8.com/highlight/detail?id=2590036549","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590036549?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:15","pubTimestamp":1765487700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUAVDRY9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2590549240","title":"Chief Scientific Officer Randall Moreadith Reports Disposal of Serina Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590549240","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590549240?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:11","pubTimestamp":1765487516,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL7XpTCZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Scientific Officer Randall Moreadith Reports Disposal of Serina Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2590553836","title":"Serina Therapeutics Inc - Submits Complete Response to FDA Clinical Hold Letter for Ser-252 Program- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590553836","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590553836?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:19","pubTimestamp":1765401546,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XG147:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2590553820","title":"Serina Therapeutics Inc - Continues Site Start-up and Regulatory Activities in Australia - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590553820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590553820?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:19","pubTimestamp":1765401546,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XG147:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2590955800","title":"Serina Therapeutics Submits Complete Response to FDA Clinical Hold for SER-252","url":"https://stock-news.laohu8.com/highlight/detail?id=2590955800","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590955800?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:18","pubTimestamp":1765401487,"startTime":"0","endTime":"0","summary":"Serina Therapeutics Inc. has submitted a complete response to the U.S. Food and Drug Administration's  clinical hold letter for its lead program, SER-252, aimed at treating advanced Parkinson's disease. The submission addresses FDA requests regarding a commonly used formulation excipient, specifically providing data supporting the use of trehalose as a subcutaneous excipient. The company is awaiting FDA feedback, with the first patient in for the registrational Phase 1b study targeted for the first quarter of 2026, pending resolution of the clinical hold and regulatory approvals. No grant or funding from multiple organizations is mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLDsw6W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2589598298","title":"Chief Scientific Officer Randall Moreadith Reports Disposal of Serina Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589598298","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589598298?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:56","pubTimestamp":1764896191,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported the disposal of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL1qXw03:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Scientific Officer Randall Moreadith Reports Disposal of Serina Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2586416289","title":"Chief Scientific Officer Randall Moreadith Disposes Common Shares of Serina Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2586416289","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586416289?lang=en_us&edition=fundamental","pubTime":"2025-11-26 10:20","pubTimestamp":1764123638,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL4RHV8M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Scientific Officer Randall Moreadith Disposes Common Shares of Serina Therapeutics Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":59,"code":"91000000","status":"200"}]}}